NASDAQ:BGMS

Cyclacel Pharmaceuticals Q3 2026 Earnings Results & Report

Cyclacel Pharmaceuticals logo
$0.61 +0.04 (+6.28%)
Closing price 03:59 PM Eastern
Extended Trading
$0.65 +0.04 (+7.06%)
As of 07:39 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cyclacel Pharmaceuticals reported Q3 2026 earnings on November 12, 2026. The company reported EPS of -$0.07, while revenue was $454 thousand.

Earnings Announcement Details

Quarter
Q3 2026
Time
After Market Closes

Cyclacel Pharmaceuticals EPS Results

Actual EPS
-$0.07
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Cyclacel Pharmaceuticals Revenue Results

Actual Revenue
$454 thousand
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Cyclacel Pharmaceuticals Q3 2026 Earnings FAQ

Cyclacel Pharmaceuticals (NASDAQ:BGMS) reported earnings of -$0.07 per share for Q3 2026. The report was announced on Thursday, November 12, 2026.

Cyclacel Pharmaceuticals reported revenue of $454 thousand for Q3 2026.

Cyclacel Pharmaceuticals Earnings Headlines

Cyclacel Pharmaceuticals (NASDAQ:BGMS) Stock Falls 9.3% - Should You Sell?
Top Trader Reveals Stunning Black Friday Deal
Others paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Trading's Thomas Wood calls it one of the firm's most powerful proprietary trading indicators, and says the company has never run a deal like this before. There are no strings attached, just a steep Black Friday discount on a tool built for traders.tc pixel
See More Cyclacel Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cyclacel Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cyclacel Pharmaceuticals and other key companies, straight to your email.

About Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals (NASDAQ:BGMS) is a clinical-stage biopharmaceutical company focused on developing medicines for cancer. Its research has centered on compounds that target cell-cycle regulation and other processes involved in cancer-cell growth.

The company’s investigational drug candidates have included fadraciclib, a cyclin-dependent kinase inhibitor, and sapacitabine, an oral nucleoside analogue. These candidates have been studied for potential use in hematologic cancers and solid tumors; they are not approved medicines.

Founded in the United Kingdom, Cyclacel has operated in both the U.K. and the United States. Spiro Rombotis has served as the company’s president and chief executive officer.

View Cyclacel Pharmaceuticals Profile